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The endocannabinoid system may be involved in the pathogenesis of depression by interacting with 
the serotonergic system. In preliminary studies, it has been reported that URB597 (a fatty acid amine 
hydrolase inhibitor) may exhibit antidepressant actions by increasing anandamide levels. The aim of 
this study was to evaluate if seven days administration of URB597 induces similar behavioural, 
neurochemical and functional adaptive changes to those induced by fluoxetine, using the animal 
model of depression of bilateral olfactory bulbectomy (OB) in mice. 
The experiments were carried out in C57BL/6 mice (25±0.1 g). All in vivo experiments were conducted 
under standard housing conditions (21±0.1ºC). Olfactory bulbectomy was performed under isofluorane 
anaesthesia and the experiments performed four weeks after surgery. Animals were treated with 1% 
DMSO i.p. (control group), fluoxetine (160 mg/l p.o.) or URB597 (0.3 mg/kg i.p.) and the experiments 
were carried out 24 hours after the last administration. Statistical analysis of the results was made 
using One-way Anova or unpaired Student t-test where appropriate (level of significance p< 0.05). 
First, behavioural testing was carried out in naïve mice in order to evaluate the possible 
antidepressant activity of URB597. Immobility time in the forced swimming test was decreased after 
URB597 administration (21.2±7.4% of reduction vs control, n=8 for both groups; p<0.05) although no 
changes were found in the anhedonic paradigm of sucrose intake. Regarding 5-HT1A receptors, no 
changes were observed in 5-HT1A receptor density, however, URB597, unlike fluoxetine, increased the 
efficacy of 8-OH-DPAT to stimulate [35S]GTPγS binding in the CA3 (+15.2±5.7%, n=11 for both 
groups; p<0.05). Also, 8-OH-DPAT-induced hypothermia (-2.7±0.4ºC in saline-treated animals; n=8) 
was attenuated by URB597 (-1.5±0.3, n=8; p< 0.01), as observed with fluoxetine (-0.6 ±0.2, n=5; p< 
0.01). On the other hand, both URB597 and fluoxetine decreased BDNF mRNA expression in the 
hippocampus. 
Olfactory bulbectomy induced an anhedonic response, an increase in 5-HT1A receptor density and an 
increase in BDNF mRNA expression in some cortical areas. Subchronic fluoxetine and URB597 were 
not able to modulate these behavioural and neurochemical changes induced by OB. However, 
URB597 reduced the efficacy of 8-OH-DPAT to stimulate [35S]GTPγS binding in dorsal raphe nucleus 
(-14.2±3.8% vs OB-vehicle, n=5 for both groups; p<0.05) and a similar effect was observed with 
fluoxetine (-14.6±6,2%, n=5; p<0.05). Finally, 8-OH-DPAT-induced hypothermia was enhanced in OB 
mice (-3.2±0.3ºC, n=6 vs -2.3±0.2ºC, n=5 for OB-vehicle and sham respectively; p< 0.01). This 5-
HT1A-receptor hypersensitivity induced by OB was totally reversed following subchronic URB597 and 
fluoxetine. 
In conclusion, URB597 exhibits a quite similar profile to the antidepressant fluoxetine in normal and 
OB mice. It has been described that olfactory bulbectomy is a validated model of depression in which 
neurochemical and behavioural changes are reversed by chronic administration of clinically effective 
antidepressants. Our findings demonstrate the existence of some neurochemical and functional 
changes after 7 days treatment with URB597, as observed with fluoxetine, which may be contributing 
to its antidepressant profile. 
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